Abstract
Background:Multiple myeloma (MM) is an incurable clonal plasma cell malignancy. The constitutive expression of HIF-1α in MM suggests that inhibition of HIF-1α-mediated transcription represents an interesting target in MM.Methods:As p300 is a crucial co-activator of hypoxia-inducible transcription, disrupting the complex HIF-1α/p300 to target HIF activity appears to be an attractive strategy.Results:We reported that chetomin, an inhibitor of HIF-1α/p300 interaction, exhibits antitumour activity in human myeloma cell lines and primary MM cells from patients.Conclusions:Our data suggest that chetomin may be of clinical value in MM and especially for patients characterised by a high EP300/HIF-1α expression and a poor prognosis.
Author supplied keywords
Cite
CITATION STYLE
Viziteu, E., Grandmougin, C., Goldschmidt, H., Seckinger, A., Hose, D., Klein, B., & Moreaux, J. (2016). Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma. British Journal of Cancer, 114(5), 519–523. https://doi.org/10.1038/bjc.2016.20
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.